Terminology Service < Semantic Lookup Platform

All terms in NCIT

Label	Id	Description
Performed Notification Message Title	NCIT_C93931	[The subject of the notification.]
BAMBI wt Allele	NCIT_C54368	[Human BAMBI wild type allele is located within 10p12.3-p11.2 and is approximately 6 kb in length. This allele, which encodes BMP and activin membrane-bound inhibitor homolog protein, may play a role in the attenuation of transforming growth factor-beta signaling.]
BAMBI Gene	NCIT_C24632	[This gene plays a role in signal transduction.]
Performed Observation Body Position Code	NCIT_C93932	[A coded value specifying the 3-dimensional spatial orientation of a subject during a particular observation.]
Body Position Code	NCIT_C93521	[A coded value specifying the 3-dimensional spatial orientation of an entity.]
BCAR3 wt Allele	NCIT_C54369	[Human BCAR3 wild-type allele is located in the vicinity of 1p22.1 and is approximately 285 kb in length. This allele, which encodes breast cancer anti-estrogen resistance protein 3, plays a role in cellular proliferation and tyrosine kinase signal transduction.]
BCAR3 Gene	NCIT_C20770	[This gene plays a role in cell cycle regulation and tumorigenesis.]
Performed Observation Focal Date Range	NCIT_C93933	[The time period in which the observation result is held to be true.]
Focal Date Range	NCIT_C93567	[The time period in which the entity is held to be true.]
Performed Observation Focal Duration	NCIT_C93934	[The quantity of time in which the observation result is held to be true.]
Focal Duration	NCIT_C93568	[The period of time in which the entity, activity, event or result is held to be true.]
Performed Observation Method Code	NCIT_C93935	[A coded value specifying the technique used to perform the observation.]
Performed Observation Result Baseline Indicator	NCIT_C93936	[Specifies whether the result is a starting point to which other results may be compared.]
Baseline Indicator	NCIT_C93514	[Specifies whether the entity is a starting point to which other things may be compared.]
Performed Observation Result Body System Code	NCIT_C93937	[A coded value specifying the anatomical structure that consists of organs and organ subclasses responsible for certain body functions.]
Body System Code	NCIT_C93522	[A coded value specifying the anatomical grouping that consists of organs and organ subclasses that are together responsible for certain body functions.]
Idronoxil Suppository NOX66	NCIT_C132257	[A proprietary, suppository-based formulation composed of idronoxil, a synthetic flavonoid derivative, surrounded by a proprietary lipid that protects idronoxil from phase 2 degradation, with potential chemo- and radio-sensitizing activities. Upon administration, idronoxil blocks the activity of ecto-NOX disulfide-thiol exchanger 2 (ENOX2; tNOX), a tumor-specific external NADH oxidase that maintains the transmembrane electron potential across the plasma membrane and is overexpressed in certain cancer cell types while absent in normal, healthy cells. Loss of this potential directly inhibits certain pro-survival signal transduction pathways, such as the PARP1/PI3 kinase/Akt signaling pathway. The inhibition of these pathways prevents resistance to standard chemo- and radio-therapy and makes tumor cells more susceptible to the anti-tumor activity of conventional chemotherapeutic agents and radiotherapy. The formulation prevents detoxification of idronoxil to an inactive form by bypassing phase 2 metabolism; this increases idronoxil's bioavailability as compared to idronoxil alone.]
STING Agonist MK-1454	NCIT_C132258	[: A synthetic cyclic dinucleotide (CDN) and agonist of stimulator of interferon genes protein (STING), with potential immunoactivating and antineoplastic activities. Upon intratumoral (IT) administration, STING agonist MK-1454 binds to STING and activates the STING pathway, which promotes IKK-related kinase TANK-binding kinase 1 (TBK1) signaling and activates nuclear factor-kappa B (NF-kB) and interferon regulatory factor 3 (IRF3) in immune cells in the tumor microenvironment; this leads to the production of pro-inflammatory cytokines, including interferons (IFNs). Specifically, expression of IFN-beta (IFNb) enhances the cross-presentation of tumor-associated antigens by CD8alpha-positive and CD103-positive dendritic cells (DCs) to cytotoxic T-lymphocytes (CTLs). This results in a CTL-mediated immune response against tumor cells and causes tumor cell lysis.]
Study Site Dissolved	NCIT_C132259	[An indication that a study site has closed down and is no longer participating in a study.]
Study Site Status	NCIT_C70783	[A business process state of a site in relation to its approval status, authorization for patient enrollment, and other protocol-specific activities in the framework of a particular clinical study.]